Addex Therapeutics’ Phase 2 Epilepsy Clinical Study to Continue

Swiss pharmaceutical company, Addex Therapeutics (Nasdaq: ADXN), has announced that an Independent Interim Review Committee has recommended the continuation of its Phase 2 clinical study of ADX1149 for epilepsy.

The clinical study is being conducted by Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.


The Independent Interim Review Committee recommended the continuation of the study following a review of unblinded data from Part 1 of patient Cohort 1.

Addex believes the continuation of the study “suggests ADX71149 is potentially safe and well tolerated and may have a positive impact on this patient population.

”The multi-center Phase 2 study has been designed to assess the efficacy, safety, tolerability, and pharmacokinetics of ADX71149 in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.

Up to 3 doses (low, medium, high) of ADX71149 will be evaluated in up to 160 patients.

There is an urgent need for more effective epilepsy treatments with improved tolerability and safety. 

About Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company developing and commercializing an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex’s lead drug candidate, ADX71149, is in a Phase 2 clinical trial for the treatment of epilepsy. Addex’s second clinical program, dipraglurant, is under evaluation for future development in a range of indications. Addex is also advancing a broad preclinical pipeline, which includes development of a range of GABAB PAMs for CMT1A, chronic cough and several types of pain, mGlu7 NAM for stress related disorders, mGlu2 NAM for mild neurocognitive disorders and depression, M4 PAM for schizophrenia and other forms of psychosis, as well as mGlu4 PAM and mGlu3 PAM.

Share This Article


About the Author

Addex Therapeutics’ Phase 2 Epilepsy Clinical Study to Continue

Editor Prism MarketView